Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
figureposted on 15.02.2021, 14:18 by Adis journals on behalf of, Susan Hutchinson, David W. Dodick, Christina Treppendahl, Nathan L. Bennett, Sung Yun Yu, Hua Guo, Joel M. Trugman
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.